RBC Capital Remains a Hold on Applied Therapeutics (APLT)
RBC Capital's Brian Abrahams maintained a Hold rating on Applied Therapeutics with a price target of $1.00. The company's shares closed at $0.27. Abrahams has an average return of 2.8% and a 47.11% success rate. Applied Therapeutics has a Moderate Buy consensus with a price target of $3.00.
In a report released on November 13, Brian Abrahams from RBC Capital maintained a Hold rating on Applied Therapeutics, with a price target of $1.00. The company’s shares closed yesterday at $0.27.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Incyte, and Neurocrine. According to TipRanks, Abrahams has an average return of 2.8% and a 47.11% success rate on recommended stocks.
Applied Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
